AbbVie Inc. $ABBV Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. cut its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,828,108 shares of the company’s stock after selling 117,438 shares during the quarter. AbbVie comprises about 0.6% of Sumitomo Mitsui Trust Group Inc.’s holdings, making the stock its 27th largest position. Sumitomo Mitsui Trust Group Inc. owned 0.22% of AbbVie worth $1,001,395,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ABBV. Corient Private Wealth LP acquired a new stake in AbbVie during the 2nd quarter worth about $559,736,000. Legal & General Group Plc bought a new position in shares of AbbVie in the 2nd quarter worth about $2,905,952,000. Jupiter Topco LLC bought a new position in shares of AbbVie in the 2nd quarter worth about $1,560,354,000. Canada Pension Plan Investment Board acquired a new position in shares of AbbVie in the 2nd quarter valued at about $817,473,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of AbbVie in the 2nd quarter valued at about $655,268,000. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on ABBV. HSBC upped their target price on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Rothschild & Co Redburn lifted their target price on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Bank of America reissued a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Wells Fargo & Company boosted their price target on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Finally, Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and increased their price target for the stock from $235.00 to $300.00 in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.86.

AbbVie Trading Up 1.4%

AbbVie stock opened at $294.80 on Friday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $298.74. The firm has a market capitalization of $520.85 billion, a price-to-earnings ratio of 50.74, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24. The firm’s fifty day moving average price is $269.35 and its two-hundred day moving average price is $237.23.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the previous year, the firm posted $1.86 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, research analysts forecast that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is currently 195.48%.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.